INCY | tickerfilter.com

Fundamental analysis

33%

Profitability 0%

Dept financing 42%

Liquidity 75%

Performance 52%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.64%

1 Month

6.38%

3 Months

-8.41%

6 Months

9.27%

1 Year

67.69%

2 Year

85.32%

Key data

Stock price

$96.22

P/E Ratio

15.07

DAY RANGE

$94.93 - $97.24

EPS

$6.59

52 WEEK RANGE

$57.29 - $112.29

52 WEEK CHANGE

$65.90

MARKET CAP

19.391 B

YIELD

N/A

SHARES OUTSTANDING

199.014 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-29-2025

BETA

0.75

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,368,525

AVERAGE 30 VOLUME

$1,340,132

Company detail

CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993

Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY - INCYTE CORP